News & Updates
Filter by Specialty:
Medicine uptitration amps up RDN benefit for drug-resistant hypertension
In patients with multidrug-resistant hypertension (HTN), the blood pressure (BP)-lowering benefit of renal denervation (RDN) achieved at 2 months was amplified when a stepped-care medication escalation protocol was added between 2 and 6 months, updates from the RADIANCE-HTN TRIO trial have shown.
Medicine uptitration amps up RDN benefit for drug-resistant hypertension
14 Nov 2021
Chemoimmunotherapeutic agents boost lymphocytic leukaemia survival
The introduction and use of chemoimmunotherapeutic agents such as rituximab, ofatumumab, and obinutuzumab has led to population-level improvements in survival from chronic lymphocytic leukaemia (CLL), a recent study has found.
Chemoimmunotherapeutic agents boost lymphocytic leukaemia survival
14 Nov 2021
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
About a third of patients who present to an emergency department with recent-onset low back pain fail to recover within 12 months, with factors such as higher pain levels and more pain sites, among others, being prognostic of complete nonrecovery within 6 months, according to a study.
Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain
13 Nov 2021
Noncardiac surgeries up MI risk post-implantation of DES in ACS, SAP patients
In acute coronary syndrome (ACS) and stable angina pectoris (SAP) patients, undergoing surgery within a year after implantation of drug-eluting stent (DES) increases the risk of myocardial infarction (MI) and death, a recent study has found.
